PMID- 21943869
OWN - NLM
STAT- MEDLINE
DCOM- 20120325
LR  - 20220410
IS  - 1873-281X (Electronic)
IS  - 1472-9792 (Linking)
VI  - 92
IP  - 1
DP  - 2012 Jan
TI  - Immunogenetics of HIV and HIV associated tuberculosis.
PG  - 18-30
LID - 10.1016/j.tube.2011.08.004 [doi]
AB  - Tuberculosis (TB) is the frequent major opportunistic infection in HIV-infected 
      patients, and is the leading cause of mortality among HIV-infected patients. 
      Genetic susceptibility to TB in HIV negative subjects is well documented. Since 
      coinfections can influence the way in which immune system respond to different 
      pathogens, genetic susceptibility to TB in HIV patients might also change. 
      Studies from India and other parts of the world have shown that genetic 
      susceptibility to TB is influenced by HIV infection. In the present review, we 
      emphasize the role of genetic factors in determining susceptibility to HIV 
      infection, disease progression and development of TB in HIV-infected patients. 
      Polymorphisms in human leukocyte antigen (HLA), MBL2, CD209, vitamin D receptor, 
      cytokine, chemokine and chemokine receptor genes have been shown to be associated 
      with development of TB in HIV patients. However, the results are inconclusive and 
      larger well-defined studies with precise clinical data are required to validate 
      these associations. Apart from candidate gene approach, genome-wide association 
      studies are also needed to unravel the unknown or to establish the previously 
      reported genetic associations with HIV associated TB. Despite the preliminary 
      status of the reported associations, it is becoming clear that susceptibility to 
      development of TB in HIV patients is influenced by both environmental and genetic 
      components. Understanding the genetic and immunologic factors that influence 
      susceptibility to TB in HIV patients could lead to novel insights for vaccine 
      development as well as diagnostic advances to target treatment to those who are 
      at risk for developing active disease.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Raghavan, S
AU  - Raghavan S
AD  - Department of Immunology, Tuberculosis Research Centre (ICMR), Mayor V.R. 
      Ramanathan Road, Chetput, Chennai 600031, India.
FAU - Alagarasu, K
AU  - Alagarasu K
FAU - Selvaraj, P
AU  - Selvaraj P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110922
PL  - Scotland
TA  - Tuberculosis (Edinb)
JT  - Tuberculosis (Edinburgh, Scotland)
JID - 100971555
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - AIDS-Related Opportunistic Infections/epidemiology/*genetics/immunology
MH  - Africa/epidemiology
MH  - Antitubercular Agents/*therapeutic use
MH  - Brazil/epidemiology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - HIV-1/*genetics
MH  - Humans
MH  - India/epidemiology
MH  - Male
MH  - *Polymorphism, Genetic
MH  - Tuberculosis/epidemiology/*genetics/immunology
EDAT- 2011/09/29 06:00
MHDA- 2012/03/27 06:00
CRDT- 2011/09/28 06:00
PHST- 2011/07/07 00:00 [received]
PHST- 2011/08/08 00:00 [accepted]
PHST- 2011/09/28 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/03/27 06:00 [medline]
AID - S1472-9792(11)00151-X [pii]
AID - 10.1016/j.tube.2011.08.004 [doi]
PST - ppublish
SO  - Tuberculosis (Edinb). 2012 Jan;92(1):18-30. doi: 10.1016/j.tube.2011.08.004. Epub 
      2011 Sep 22.